Bei Akademie registrieren
TAK, US8740602052

Takeda stock: Japan launch adds ELAHERE oncology milestone

Published on 11/14/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Takeda stock drew attention after the Japan launch of ELAHERE for recurrent ovarian cancer. The rollout adds a commercial oncology milestone.

Japan launch adds commercial milestone

  • Takeda launched ELAHERE in Japan for a defined group of patients with recurrent ovarian cancer.
  • The product is the first and only antibody-drug conjugate approved in Japan for this indication.
  • The launch expands Takeda's oncology portfolio alongside its broader pipeline of new medicines.
TAK, US8740602052, Illustration mit AI erstellt.
TAK, US8740602052, Illustration mit AI erstellt.

Takeda announced on Friday, November 13, 2026, the launch of ELAHERE in Japan for patients with folate receptor alpha-positive, platinum-resistant recurrent ovarian cancer. The company's Takeda Pharmaceuticals release describes ELAHERE as the first and only antibody-drug conjugate approved in Japan for this indication.

Japan launch expands oncology reach

ELAHERE, whose generic name is mirvetuximab soravtansine, received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare on September 16, 2026. The approval relied on results from the MIRASOL and SORAYA trials and a Japanese Phase 1/2 study.

The treatment targets tumors expressing folate receptor alpha. A companion diagnostic from Roche supports assessment of treatment eligibility, linking the launch to a biomarker-led treatment pathway.

Commercial execution remains central

The Japan rollout adds another commercial milestone as Takeda advances new medicines across oncology and other therapeutic areas. For investors, uptake, treatment access and the company's ability to translate launches into durable growth remain key factors.

Takeda stock traded at 19.50 euros on Lang & Schwarz at 10:21 CET on Saturday, November 14, 2026.

Takeda Pharmaceutical Company Limited

  • Company: Takeda Pharmaceutical Company Limited
  • ISIN: US8740602052
  • Ticker: TAK
  • Home exchange: Tokyo Stock Exchange
  • Quote: 19.50 euros on Lang & Schwarz at 10:21 CET on November 14, 2026

Japan's broader equity backdrop is covered in Current market reports.

More news and analyses are available on the Takeda stock topic page.

Disclaimer...
en | US8740602052 | TAK | boerse | 70509885 | bgmi